Sprint Bioscience AB (publ) (STO:SPRINT)
3.680
-0.120 (-3.16%)
Nov 20, 2026, 5:29 PM CET
Sprint Bioscience AB Earnings Call Transcripts
Fiscal Year 2026
-
The discovery-only model combines fragment-based design, structural biology and an in-house DMTA engine to build a broad, partner-ready oncology portfolio. Lilly TuneLab adds AI-based ADME prediction; the five disclosed programs are ready for partnering.
Fiscal Year 2025
-
A 16-year innovation-driven company specializes in early-stage drug discovery, focusing on oncology and leveraging fragment-based design. It maintains a broad, flexible portfolio, pursues licensing, spinouts, and strategic collaborations, and is recognized for its expertise and adaptable business model.